Loyola Medicine Clinical Trials

825 Clinical Trials

To compare disease-free survival (DFS) in participants undergoing radical cystectomy for muscle-invasive urothelial carcinoma of the bladder (UCB) treated with radical cystectomy and extended pelvic lymph node dissection (PLND) compared to radical cystectomy and standard pelvic lymphadenectomy.

Enrolled
620
Status
Open
Cancer: Bladder

The goal of this registry is to establish a standardized source of observational data that can be used to report and query patient-care patterns, clinical outcomes and trends from HD IL-2 therapy in treating mM, mRCC or other malignancies.

Enrolled
1,500
Status
Open
Cancer: Kidney (Renal)
National Clinical Trial # 00840177

The purpose of this study is to test whether the complete remission (CR) rate (including CR with incomplete recovery) in patients with relapsed acute myeloid leukemia treated with a combination of chemotherapy and pravastatin is sufficiently high to warrant phase III investigation.

Enrolled
50
Status
Open
Cancer: Leukemia
National Clinical Trial # 00956007

The purpose of this study is to test whether the addition of cetuximab to radiation therapy will improve overall survival in post-operative patients with intermediate risk following surgery.

Enrolled
700
Status
Open
Cancer: Head and Neck

The purposes of this study are to determine whether the addition of erlotinib to gemcitabine adjuvant chemotherapy improves survival as compared to gemcitabine alone following R0 or R1 resection of head of pancreas adenocarcinoma (including adenocarcinoma of the head, neck and uncinate process) and to determine whether the use of concurrent fluoropyrimidine and radiotherapy following adjuvant gemcitabine-based chemotherapy further enhances survival for such patients who are without evidence of progressive disease after five cycles of gemcitabine-based chemotherapy.

Enrolled
950
Status
Open
Cancer: Pancreatic

The purpose of this study is to determine whether fulvestrant or fulvestrant + anastrazole administered for 24 weeks as neoadjuvant endocrine treatment decreases the proportion of endocrine-resistant tumors relative to patients treated with anastrozole alone; and to assess whether the five--year RFS rate among women with a modified preoperative endocrine prognostic index (PEPI) score of 0 following 24 weeks of each arm of neoadjuvant endocrine therapy is at least 95 percent.

Enrolled
2,820
Status
Open
Cancer: Breast
National Clinical Trial # 00887146

Reasons this research study is being done are to see if 1.) participants survive longer if they get treatment with the combination of both radiation therapy and temozolomide chemotherapy as compared to participants who receive treatment with just radiation therapy and 2.) participants treated with temozolomide therapy alone (without radiation therapy) have a better or worse quality of life and mental function than those participants who are treated with either the combination of radiation therapy and temozolomide or radiation therapy alone. Survival will also be monitored in the participants getting temozolomide alone.

Enrolled
488
Status
Open
Cancer: Brain

Primary objective: to compare overall survival in newly diagnosed metastatic prostate cancer patients randomly assigned to androgen deprivation therapy (ADT) + TAK-700 versus ADT + bicalutamide.;Secondary objective: (a) to compare progression free survival between the two arms.;Secondary objective: (b) to compare distributions of PSA response between the treatment arms at 7 months post-randomization.;Secondary objective: (c) to compare the qualitative and quantitative adverse events from each treatment arm.;Secondary objective: (d) to characterize the long-term survival in both treatment arms after 10 years of follow-up.;Other objective: (a) to validate the prognostic and predictive value of markers of bone turnover in newly-diagnosed metastatic hormone sensitive prostate cancer patients treated with TAK-700.;Other objective: (b) to bank serum/whole blood and tissue specimens for future use.

Enrolled
1,636
Status
Open
Cancer: Prostate

The primary aim of this multicenter study is to examine the incidence of neutrophil recovery of =500/mm3 after cord blood transplantation using CBUs that are not licensed by the Food and Drug Administration (FDA).

Enrolled
0
Status
Open
Cancer
National Clinical Trial # 01042379

The purpose of this study is to determine whether adding experimental agents to standard neoadjuvant paclitaxel (with or without trastuzumab), doxorubicin and cyclophosphamide increases the probability of pathologic complete response (pCR) over standard neoadjuvant chemotherapy for each biomarker signature established at trial entry, and to determine for each experimental agent used the predictive probability of success in a subsequent phase III trial for each possible biomarker signature.

Enrolled
800
Status
Open
Cancer: Breast

Pages